A new and experimental anti-clotting drug, cangrelor, proved better than the commonly used clopidogrel and was significantly more effective at preventing blood clots in a large trial of patients who underwent coronary stent procedures. These data, from the phase III CHAMPION PHOENIX study, were presented at the American College of Cardiology's 62nd Annual Scientific Session and published simultaneously in the New England Journal of Medicine.
Culture
MINNEAPOLIS, MN - March 9, 2013 - The use of extracorporeal membrane oxygenation (ECMO), accompanied by mechanical CPR, in patients with massive myocardial infarctions can lead to unexpected survival. These study findings are being presented March 9 at the American College of Cardiology Scientific Sessions.
ECMO is an advanced technology that functions as a replacement for a critically ill patient's heart and lungs. This is the first report of combined ECMO, mechanical CPR and therapeutic hypothermia (TH) use within a STEMI Network.
SAN FRANCISCO (March 9, 2013) — A highly anticipated study evaluating a combination of the vitamin niacin with the anti-flushing agent laropiprant finds the therapy provides no benefit to and may even be harmful for patients with vascular disease, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session. Detailed trial data is presented here for the first time.
SAN FRANCISCO (March 10, 2013) —High doses of a popular cholesterol-lowering drug significantly reduced the rate of acute kidney injury caused by dye used in imaging in acute coronary syndrome patients who underwent a coronary procedure, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session. This group of patients is at high risk for kidney damage related to contrast agents used in imaging tests.
SAN FRANCISCO (March 10, 2013) — The new Sapien XT aortic valve showed a non-significantly lower rate of death and strokes at 30 days than the original model, and both valves demonstrated notably better short-term outcomes than seen with the Sapien system in PARTNER I, according to the first results from the PARTNER II study presented today at the American College of Cardiology's 62nd Annual Scientific Session.
SAN FRANCISCO (March 10, 2013) — In a match-up of Japan's top drug-releasing stent and a new device featuring a biodegradable coating, the newcomer delivered statistically comparable one-year results, according to data from the NEXT trial presented today at the American College of Cardiology's 62nd Annual Scientific Session.
SAN FRANCISCO (March 10, 2013) — Patients with a type of coronary lesion linked with poor prognosis fared significantly better with the stent technique known as double kissing crush than with culotte stenting, according to data from the DKCRUSH-III trial presented today at the American College of Cardiology's 62nd Annual Scientific Session.
For years, researchers have developed thin films of bismuth telluride (Bi2Te3) – which converts heat into electricity or electricity to cooling – on top of gallium arsenide (GaAs) to create cooling devices for electronics. But while they knew it could be done, it was not clear how – because the atomic structures of those unlikely pair of materials do not appear to be compatible. Now researchers from North Carolina State University and RTI International have solved the mystery, opening the door to new research in the field.
(SACRAMENTO, Calif.) —A scientific survey of more than 9,700 gun retailers in the U.S. has found that gun buyers frequently try to make illegal purchases and that gun retailers take a dim view of fellow sellers who engage in illegal activity — regardless of whether they are actively breaking the law or simply looking the other way.
Cleveland Clinic research shows anemia drug does not improve health of anemic heart failure patients
EMBARGOED UNTIL 7:45 PM ET, Sunday, March 10, 2013, Cleveland: Researchers from Cleveland Clinic and Sweden-based Sahlgrenska University Hospital have found that a commonly used drug to treat anemia in heart failure patients –darbepoetin alfa – does not improve patients' health, nor does it reduce their risk of death from heart failure.
Results of the international study were presented at the American College of Cardiology's annual meeting in San Francisco on March 10 and published simultaneously online by the New England Journal of Medicine.
Even though young athletes are required to receive health screens to be cleared to play sports, those tests failed to detect important cardiovascular abnormalities in cleared players, and many were allowed to play despite suspicions of dangerous cardiovascular conditions, according to a large registry study of patients who died from sudden death, being presented March 10 by Kevin Harris, MD, research cardiologist at the Minneapolis Heart Institute Foundation (MHIF). The data is being presented at the annual American College of Cardiology Scientific Sessions in San Francisco.
A single dose of an investigational anti-inflammatory drug called inclacumab considerably reduces damage to heart muscle during angioplasty (the opening of a blocked artery), according to a recent international clinical trial spearheaded by Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, affiliated with the University of Montreal. Presented today in San Francisco at the prestigious American cardiology conference, these findings show great promise.
Transfusion of donated blood more than three weeks old results in impaired blood vessel function, a new study of hospital patients shows.
Blood banks now consider six weeks to be the maximum permitted storage time of blood for use in transfusion, but recent studies have suggested transfusing blood stored for more than a few weeks has adverse effects in patients undergoing cardiac surgery or critical care.
DETROIT – A class of medications commonly prescribed to lower blood sugar in diabetic patients appears to protect them from developing heart failure, according to a study at Henry Ford Hospital in Detroit.
"People with diabetes are at risk for developing heart failure," says Henry Ford researcher and cardiologist David Lanfear, M.D., lead author of the study. "Diabetic adults die of heart disease two to four times more than those without diabetes.
A clinical decision support tool helped physicians identify patients at high risk of bleeding complications prior to undergoing a coronary intervention procedure and helped guide the use of bleeding avoidance strategies, leading to less complications and a shorter hospital stay, according to a study being presented March 10 at the American College of Cardiology Scientific Sessions.
More than 1.3 million percutaneous coronary interventions (PCIs) are performed each year in the United States. Bleeding during and after these procedures is a common risk (3 – 6%).